Replies to post #646344 on NorthWest Biotherapeutics Inc (NWBO)

[newman2021]

yep, on page 28/29 I love this like you pointed out.

'As of September 30, 2023, the only unvested milestone was to submit an application to a regulatory which is expected to take place during November 2023'

And also on page 25, I love this.
Between May and September 2023, the Company entered into certain non-dilutive funding agreements with multiple investors, pursuant to which the Company received funding of $4.6 million related to a gain contingency. These agreements are accounted for under ASC 470 and are recognized as contingent payment obligations on the Company’s condensed consolidated balance sheet. The Company’s payment obligations only apply when such are received by the Company.

[fluteman]

Love that they are doubling down on November!

[attilathehunt]

Do you suppose the delay was due to this requirement...Needing Pediatric trial?

If so, can application be submit while preparing or does it say pediatric trial needs to be in progress?


"The Company is pursuing preparations for the pediatric clinical trials that are required to be conducted in connection with an application for approval of a new medicine for adult patients."

^^ New Language

[FeMike]

Damn Hoffy boy. As an alleged lawyer, your use of quotes in this rundown is liberal at best.

As of September 30, 2023, the only unvested milestone was to submit an application to a regulatory which is expected to take place during November 2023.

Where in the hell does the Q say this?

ETA: ah shoot, you’ve hit your two post limit for the day. Feel free to respond tomorrow and let me know where you pulled that quote from. Can’t wait.

[beartrap12]

Patents

"We are pursuing the prosecution of existing patent applications and adding intellectual property that we consider complementary to our existing intellectual property."
Any thoughts on what this sentence means? Seems like two different thoughts under the patent heading in the 10Q.
Maybe prosecuting a company that's over-stepping their patent rights?
And does pursuing "adding intellectual property" mean buying poly ICLC patent rights? Maybe the company, Oncovir? Maybe something else?

Appreciate anybody's thoughts.
Thanks, Hoffman, for your thoughts on the 10Q.

[XMaster2023]

Specials Revenue

Q3 2022: $206k
Q4 2022: $597k

Q1 2023: $880k
Q2 2023: $201k
Q3 2023: $406k

Not a bad increase in revenue.